191 related articles for article (PubMed ID: 29057047)
1. Stabilizing a Tubulysin Antibody-Drug Conjugate To Enable Activity Against Multidrug-Resistant Tumors.
Staben LR; Yu SF; Chen J; Yan G; Xu Z; Del Rosario G; Lau JT; Liu L; Guo J; Zheng B; Cruz-Chuh JD; Lee BC; Ohri R; Cai W; Zhou H; Kozak KR; Xu K; Lewis Phillips GD; Lu J; Wai J; Polson AG; Pillow TH
ACS Med Chem Lett; 2017 Oct; 8(10):1037-1041. PubMed ID: 29057047
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Cytotoxic Evaluation of Novel Tubulysin Analogues as ADC Payloads.
Leverett CA; Sukuru SC; Vetelino BC; Musto S; Parris K; Pandit J; Loganzo F; Varghese AH; Bai G; Liu B; Liu D; Hudson S; Doppalapudi VR; Stock J; O'Donnell CJ; Subramanyam C
ACS Med Chem Lett; 2016 Nov; 7(11):999-1004. PubMed ID: 27882198
[TBL] [Abstract][Full Text] [Related]
3. Glucuronide-Linked Antibody-Tubulysin Conjugates Display Activity in MDR
Burke PJ; Hamilton JZ; Pires TA; Lai HWH; Leiske CI; Emmerton KK; Waight AB; Senter PD; Lyon RP; Jeffrey SC
Mol Cancer Ther; 2018 Aug; 17(8):1752-1760. PubMed ID: 29866744
[TBL] [Abstract][Full Text] [Related]
4. Improving Antibody-Tubulysin Conjugates through Linker Chemistry and Site-Specific Conjugation.
Hamilton JZ; Pires TA; Mitchell JA; Cochran JH; Emmerton KK; Zaval M; Stone IJ; Anderson ME; Jin S; Waight AB; Lyon RP; Senter PD; Jeffrey SC; Burke PJ
ChemMedChem; 2021 Apr; 16(7):1077-1081. PubMed ID: 33369163
[TBL] [Abstract][Full Text] [Related]
5. Improved access to potent anticancer tubulysins and linker-functionalized payloads via an all-on-resin.
Ricardo MG; Llanes D; Rennert R; Jänicke P; Rivera DG; Wessjohann LA
Chemistry; 2024 May; ():e202401943. PubMed ID: 38771268
[TBL] [Abstract][Full Text] [Related]
6. Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates.
Burke PJ; Hamilton JZ; Pires TA; Setter JR; Hunter JH; Cochran JH; Waight AB; Gordon KA; Toki BE; Emmerton KK; Zeng W; Stone IJ; Senter PD; Lyon RP; Jeffrey SC
Mol Cancer Ther; 2016 May; 15(5):938-45. PubMed ID: 26944920
[TBL] [Abstract][Full Text] [Related]
7. Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism.
Tumey LN; Leverett CA; Vetelino B; Li F; Rago B; Han X; Loganzo F; Musto S; Bai G; Sukuru SC; Graziani EI; Puthenveetil S; Casavant J; Ratnayake A; Marquette K; Hudson S; Doppalapudi VR; Stock J; Tchistiakova L; Bessire AJ; Clark T; Lucas J; Hosselet C; O'Donnell CJ; Subramanyam C
ACS Med Chem Lett; 2016 Nov; 7(11):977-982. PubMed ID: 27882194
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships of tubulysin analogues.
Courter JR; Hamilton JZ; Hendrick NR; Zaval M; Waight AB; Lyon RP; Senter PD; Jeffrey SC; Burke PJ
Bioorg Med Chem Lett; 2020 Jul; 30(14):127241. PubMed ID: 32527543
[TBL] [Abstract][Full Text] [Related]
9. Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling.
Cohen R; Vugts DJ; Visser GW; Stigter-van Walsum M; Bolijn M; Spiga M; Lazzari P; Shankar S; Sani M; Zanda M; van Dongen GA
Cancer Res; 2014 Oct; 74(20):5700-10. PubMed ID: 25145670
[TBL] [Abstract][Full Text] [Related]
10. Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells.
Salomon PL; Singh R
Mol Pharm; 2015 Jun; 12(6):1752-61. PubMed ID: 25738394
[TBL] [Abstract][Full Text] [Related]
11. Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2.
Faria M; Peay M; Lam B; Ma E; Yuan M; Waldron M; Mylott WR; Liang M; Rosenbaum AI
Antibodies (Basel); 2019 Jan; 8(1):. PubMed ID: 31544817
[TBL] [Abstract][Full Text] [Related]
12. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Biological Evaluation of Tubulysin Analogues, Linker-Drugs, and Antibody-Drug Conjugates, Insights into Structure-Activity Relationships, and Tubulysin-Tubulin Binding Derived from X-ray Crystallographic Analysis.
Nicolaou KC; Pan S; Pulukuri KK; Ye Q; Rigol S; Erande RD; Vourloumis D; Nocek BP; Munneke S; Lyssikatos J; Valdiosera A; Gu C; Lin B; Sarvaiaya H; Trinidad J; Sandoval J; Lee C; Hammond M; Aujay M; Taylor N; Pysz M; Purcell JW; Gavrilyuk J
J Org Chem; 2021 Feb; 86(4):3377-3421. PubMed ID: 33544599
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
Rios-Doria J; Harper J; Rothstein R; Wetzel L; Chesebrough J; Marrero A; Chen C; Strout P; Mulgrew K; McGlinchey K; Fleming R; Bezabeh B; Meekin J; Stewart D; Kennedy M; Martin P; Buchanan A; Dimasi N; Michelotti E; Hollingsworth R
Cancer Res; 2017 May; 77(10):2686-2698. PubMed ID: 28283653
[TBL] [Abstract][Full Text] [Related]
15. Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads.
Puthenveetil S; Loganzo F; He H; Dirico K; Green M; Teske J; Musto S; Clark T; Rago B; Koehn F; Veneziale R; Falahaptisheh H; Han X; Barletta F; Lucas J; Subramanyam C; O'Donnell CJ; Tumey LN; Sapra P; Gerber HP; Ma D; Graziani EI
Bioconjug Chem; 2016 Aug; 27(8):1880-8. PubMed ID: 27412791
[TBL] [Abstract][Full Text] [Related]
16. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N
J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
[TBL] [Abstract][Full Text] [Related]
18. In vivo structural activity and optimization studies of folate-tubulysin conjugates.
Reddy JA; Dorton R; Dawson A; Vetzel M; Parker N; Nicoson JS; Westrick E; Klein PJ; Wang Y; Vlahov IR; Leamon CP
Mol Pharm; 2009; 6(5):1518-25. PubMed ID: 19630399
[TBL] [Abstract][Full Text] [Related]
19. Acquired Resistance to Antibody-Drug Conjugates.
Collins DM; Bossenmaier B; Kollmorgen G; Niederfellner G
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30897808
[TBL] [Abstract][Full Text] [Related]
20. Modulating Antibody-Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification.
Su D; Kozak KR; Sadowsky J; Yu SF; Fourie-O'Donohue A; Nelson C; Vandlen R; Ohri R; Liu L; Ng C; He J; Davis H; Lau J; Del Rosario G; Cosino E; Cruz-Chuh JD; Ma Y; Zhang D; Darwish M; Cai W; Chen C; Zhou H; Lu J; Liu Y; Kaur S; Xu K; Pillow TH
Bioconjug Chem; 2018 Apr; 29(4):1155-1167. PubMed ID: 29481745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
